Similar articles

• Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

  Pollock C, Stefánsson B, Reyner D, Rossing P, Sjöström CD, Wheeler DC, Langkilde AM, Heerspink HJL. Pollock C, et al. Lancet Diabetes Endocrinol. 2019 Jun;7(6):429-441. doi: 10.1016/S2213-8587(19)30086-5. Epub 2019 Apr 13. Lancet Diabetes Endocrinol. 2019. PMID: 30992195 Clinical Trial.
• Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?

  Sternlicht HK, Bakris GL. Sternlicht HK, et al. Lancet Diabetes Endocrinol. 2020 Jul;8(7):553-555. doi: 10.1016/S2213-8587(20)30185-6. Lancet Diabetes Endocrinol. 2020. PMID: 32559465 No abstract available.
• Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.

  Birnbaum Y, Bajaj M, Yang HC, Ye Y. Birnbaum Y, et al. Cardiovasc Drugs Ther. 2018 Apr;32(2):135-145. doi: 10.1007/s10557-018-6778-x. Cardiovasc Drugs Ther. 2018. PMID: 29508169
• Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.

  Scheen AJ. Scheen AJ. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1303-1316. doi: 10.1080/17512433.2017.1389645. Epub 2017 Oct 18. Expert Rev Clin Pharmacol. 2017. PMID: 28984487 Review.
• Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?

  Goldenberg RM, Verma S, Perkins BA, Gilbert JD, Zinman B. Goldenberg RM, et al. Can J Diabetes. 2017 Feb;41(1):6-9. doi: 10.1016/j.jcjd.2016.08.001. Epub 2016 Nov 10. Can J Diabetes. 2017. PMID: 27838228 Review. No abstract available.